Johnson & Johnson
NASDAQ: JNJKey stats
Price chart
About Johnson & Johnson
Pharmaceuticals
Company profile
- IPO date
- Sep 25, 1944
- Website
- www.jnj.com
Healthcare peers
How JNJ compares to other large companies in the same sector.
| Company | Price | Today | Market cap | P/E |
|---|---|---|---|---|
 LLY Eli Lilly and Company | $1004.92 | -0.18% | $946.37B | 37.44 |
 ABBV AbbVie Inc. | $210.39 | -0.18% | $371.72B | 87.96 |
 UNH UnitedHealth Group | $393.85 | -1.31% | $358.78B | 30.14 |
 MRK Merck & Co. | $111.38 | -1.79% | $275.09B | 30.79 |
 PFE Pfizer Inc. | $25.33 | -1.63% | $144.17B | 19.57 |
Wall Street analyst ratings
DollarScout analysis
Editorial, not advice. See our methodology.
Bull case
Johnson & Johnson's competitive moat is built on its diversified product portfolio across pharmaceuticals, medical devices, and consumer health sectors. This diversification protects J&J from sector-specific downturns and provides a steady revenue stream. In pharmaceuticals, blockbusters like Stelara and Imbruvica drive substantial sales growth. The company’s ability to innovate and expand pipeline capabilities provides a growth driver, evident in its strong R&D spending. Valuation support comes from a solid P/E ratio of 21.43 compared to industry standards, suggesting stability. With a market cap of $574.36B, J&J commands significant market influence, which is appealing for investors seeking steady capital appreciation paired with a dividend yield of 2.1556%.
Bear case
Despite its size and stability, Johnson & Johnson isn't without risks. Legal challenges, particularly product liability litigations, pose potential financial pitfalls. Competition in the pharmaceutical industry is fierce, with rivals constantly developing alternative therapies that could erode J&J's market share. Additionally, the company's growth may be constrained by its mature market positioning, limiting upside potential compared to more nimble competitors. The healthcare sector is also subject to political and regulatory changes that could impact profitability. Any disruption in its supply chain due to geopolitical tensions or pandemic-related challenges could adversely affect operations.
Who should buy JNJ
JNJ is ideal for long-term dividend investors with a 10+ year horizon who want reliable income and steady growth. It's suitable for those with moderate risk tolerance looking for a blue-chip stock to anchor a diversified portfolio. This stock fits well into the core holdings of defensive investors focused on stability rather than high-growth ventures.
Key risks
- Legal liabilities related to product defects and healthcare regulations. - Stiff competition from emerging pharmaceutical companies with innovative technologies. - Potential impacts of healthcare policy and reforms which may affect pricing and reimbursement. - Geopolitical risks and supply chain disruptions affecting global operations.
Where to buy JNJ
Open an account with a broker we've reviewed and start trading Johnson & Johnson today.
Want to practice first? Try the free Stock Trading Simulator with $100,000 virtual cash.
Recent JNJ news
On episode 168 of the Rich Habits Podcast, co-host Robert Croak made a pitch that sounds almost too easy to be a strategy. He noted, “The easiest stream of income you can build because you’re already probably sitting on the cash. You just need to park it in the right vehicles.” His co-host, Austin, then ... Why Keeping Emergency Cash in Checking Costs You $15,000 Over a Decade
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full analysis here.
Soros Fund Management: Soros Fund Management LLC reports share stake of 2.5 million shares in Blue Owl Capital Corporation - SEC FILING Soros Fund Management LLC reports share stake of 173,489...
The retirement plan looked straightforward until March 2026. A 64-year-old couple in Pennsylvania had built a $2.4 million portfolio around a familiar target: roughly $96,000 a year in retirement spending supported by the classic 4% withdrawal framework. Then a new possibility entered the picture. The husband’s 88-year-old father, recently widowed and living alone in Florida, ... What Retirement Really Looks Like at 64 With $2.4 Million and a Father Moving Into the Guest Room Next Year
After 22 years, a couple sold their restaurant and suddenly found themselves staring at a very different balance sheet. The sale dropped $1.1 million in cash onto the table, adding to the $480,000 already sitting in a SEP-IRA. On paper, that looks like roughly $1.58 million in investable assets before taxes enter the chat like ... If You Have $480,000 Saved at 67 and Just Sold a Restaurant for $1.1 Million Cash, Here Is the Income Plan That Actually Holds
ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.
One member of Congress buys the same stocks every year. Here's how dividends are involved.
MOUNTAIN VIEW, Calif., May 15, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni Association at Columbia University Vagelos College of Physicians and Surgeons. This award honors VP&S alumni who are making transformational contributions to biomed
Disclaimer: The information on this page is provided for informational and educational purposes only and should not be considered financial, investment, or trading advice. DollarScout does not recommend buying or selling any specific security. Stock data may be delayed. Past performance is not indicative of future results. Always do your own research and consult a licensed financial advisor before making investment decisions.